{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-015650","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.236913+00:00","generated_at":"2026-06-04T06:55:59.832674+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M","bullets":["Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.","Full-year 2023 revenue $33.4M vs $36.2M; net loss $10.8M ($0.31 EPS) vs $5.6M loss.","Recorded $2.3M goodwill impairment in dermatology recurring procedures segment.","Installed XTRAC base 923 devices; launched TheraClear X acne system with 92 devices in operation.","Dr. Dolev Rafaeli appointed Vice-Chairman, President and CEO in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-015650","json":"https://secwatch.observer/filing/0001140361-24-015650.json","markdown":"https://secwatch.observer/filing/0001140361-24-015650.md","text":"https://secwatch.observer/filing/0001140361-24-015650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124015650/0001140361-24-015650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124015650/ef20025035_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:55:59.832674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}